Xoma Shifts Focus To Endocrine Drugs
In an effort to cut costs, the company, which has yet to bring a drug to market, has abandoned its one-time savior program.
The San Francisco Business Times:
Biotech Zombie Xoma Plods Toward Its Target
Xoma Corp. over 30 years has lost more than $1 billion, tried out drugs in hepatitis, diabetes, hypertension, cancer, rheumatoid arthritis and acne, and has yet to bring a drug to market. And now the Berkeley company, as part of a cost-cutting initiative that included shedding half its workforce, has killed its one-time savior program, the experimental drug gevokizumab. (Leuty, 3/10)